Secondly, the specific patient characteristics, such as poorer glycemic control (mean HbA1c of 8.31% in our cohort), more severe hyperglycemia, or the co-occurrence of AIS, might counteract the potential BDNF-elevating effects of metformin. The gene discussed is BDNF; the disease is Hyperglycemia.